Regeneron Pharmaceuticals, Inc. (REGN)
- Previous Close
893.99 - Open
914.99 - Bid 895.72 x 100
- Ask 896.79 x 200
- Day's Range
891.46 - 920.73 - 52 Week Range
684.81 - 998.33 - Volume
501,396 - Avg. Volume
470,185 - Market Cap (intraday)
98.437B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
25.77 - EPS (TTM)
34.80 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1,048.72
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
www.regeneron.comRecent News: REGN
Performance Overview: REGN
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REGN
Valuation Measures
Market Cap
98.44B
Enterprise Value
90.30B
Trailing P/E
25.79
Forward P/E
19.96
PEG Ratio (5yr expected)
1.45
Price/Sales (ttm)
7.77
Price/Book (mrq)
3.79
Enterprise Value/Revenue
6.88
Enterprise Value/EBITDA
19.24
Financial Highlights
Profitability and Income Statement
Profit Margin
30.14%
Return on Assets (ttm)
8.49%
Return on Equity (ttm)
16.26%
Revenue (ttm)
13.12B
Net Income Avi to Common (ttm)
3.95B
Diluted EPS (ttm)
34.80
Balance Sheet and Cash Flow
Total Cash (mrq)
10.84B
Total Debt/Equity (mrq)
10.74%
Levered Free Cash Flow (ttm)
2.76B
Research Analysis: REGN
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: REGN
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Daily – Vickers Top Buyers & Sellers for 02/20/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Market Digest: AN, FE, GPN, MGM, OMC, REGN, CHTR, CTVA
How High Is Up?
Analyst Report: Regeneron Phars, Inc
Regeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 13,450 employees worldwide, and is based in Tarrytown, New York.
RatingBullishPrice Target